More than 50 pharmaceutical products, including widely used calcium and vitamin D3 supplements, anti-diabetic medications, and high blood pressure treatments, have been flagged for failing quality tests by India’s drug regulatory authority. The Central Drugs Standards Control Organisation (CDSCO) recently issued a “Not of Standard Quality (NSQ) Alert” for 53 drugs in its latest monthly report.
Details of the Failed Drugs
The NSQ alerts are generated through random sampling conducted by state drug officers. Among the notable products listed are Shelcal vitamin C and D3 tablets, vitamin B complex and vitamin C softgels, the antacid Pan-D, paracetamol tablets IP 500 mg, the anti-diabetic drug Glimepiride, and the hypertension medication Telmisartan.
Manufacturers of these drugs include Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Meg Lifesciences, and Pure & Cure Healthcare. Notably, Metronidazole, a common treatment for stomach infections produced by HAL, is also included in the list of substandard drugs.
Impact on Public Health
The revelation of these substandard drugs raises significant concerns regarding public health and safety, as many of these medications are essential for managing chronic conditions. The CDSCO’s findings underscore the need for stringent quality control measures in the pharmaceutical industry to ensure the safety and efficacy of medications available to consumers.
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER
